A Randomised,Double-blind,Placebo-controlled,Multi National,Phase III Trial to Assess the Efficacy and Safety of 300 IR Sublingual Immunotherapy Administered as Allergen-based Tablets Once Daily to Adolescents and Children Above the Age of 5 Years, Suffering From House Dust Mite Allergic Rhinitis.

Trial Profile

A Randomised,Double-blind,Placebo-controlled,Multi National,Phase III Trial to Assess the Efficacy and Safety of 300 IR Sublingual Immunotherapy Administered as Allergen-based Tablets Once Daily to Adolescents and Children Above the Age of 5 Years, Suffering From House Dust Mite Allergic Rhinitis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs S 524101 (Primary)
  • Indications Hypersensitivity; Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 22 Mar 2012 Actual initiation date changed from Oct 2009 to 16 Sep 2009 as reported by European Clinical Trials Database.
    • 22 Mar 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 19 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top